Ketamine and Lidocaine Infusion in Refractory Chronic Migraine
NCT ID: NCT06935552
Last Updated: 2025-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
EARLY_PHASE1
44 participants
INTERVENTIONAL
2025-06-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ketamine for Refractory Chronic Migraine: a Pilot Study
NCT03896256
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
NCT07061847
Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches
NCT05306899
Status Migrainosus - Differentiating Between Responders and Non-responders
NCT03066544
The Efficacy Of Lidocaine Infusion IN Chronic Unilateral Migraine Headache
NCT06109389
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ketamine
will receive ketamine
Ketamine infusion
group A will receive ketamine intravenous infusion
Lidocaine
will receive lidocaine
Lidocaine Intravenous Infusion
group B will receive lidocaine intravenous infusion
Dextrose
Dextrose 5% in water
group C will only receive Dextrose 5% in water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketamine infusion
group A will receive ketamine intravenous infusion
Lidocaine Intravenous Infusion
group B will receive lidocaine intravenous infusion
Dextrose 5% in water
group C will only receive Dextrose 5% in water
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Are reliable and willing to make themselves available for the duration of the study and are willing to follow up.
3. Men or women older than 18years of age.
4. clear written informed consent from each participant in the trial.
5. Adult patients with refractory migraine or refractory chronic migraine defined according to the American headache society
Exclusion Criteria
2. presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study
3. participation in any other type of medical research that may interfere with the interpretation of the study.
4. patients with hemocoagulation disorders, local infection or those who refused to consent
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AbdElRahman Mohamed Mohamed Mohamed
Resident doctor in neurology and psychiatry department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nageh Fouly Kamel, PhD.
Role: STUDY_CHAIR
Assiut University
Mohamed Ahmed Abdelhameed, PhD.
Role: STUDY_CHAIR
Assiut University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Schulman EA, Lake AE 3rd, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, Lipton RB. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008 Jun;48(6):778-82. doi: 10.1111/j.1526-4610.2008.01132.x. Epub 2008 May 14.
Ray JC, Cheng S, Tsan K, Hussain H, Stark RJ, Matharu MS, Hutton E. Intravenous Lidocaine and Ketamine Infusions for Headache Disorders: A Retrospective Cohort Study. Front Neurol. 2022 Mar 9;13:842082. doi: 10.3389/fneur.2022.842082. eCollection 2022.
Lauretti GR. Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6. doi: 10.1590/s0034-70942008000300011. English, Portuguese.
Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998 Nov;87(5):1186-93. doi: 10.1097/00000539-199811000-00039. No abstract available.
Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010 May;30(5):599-609. doi: 10.1111/j.1468-2982.2009.01941.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ketamine vs lidocaine in RCM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.